Becton Dickinson & Co. (BDX) risk factors: FY2025 10-K

1. Global economic conditions, including inflation and supply chain disruptions, could continue to adversely affect our operations.
2. Our international operations subject us to certain business risks.
3. The medical technology industry is very competitive.
4. Market dynamics, changes in reimbursement practices and coverage policies, third-party payer cost containment measures and health insurance coverage levels could affect demand for our products and the prices at which they are sold.reworded
5. Reductions in customers’ research budgets or government funding may adversely affect our business.
6. Our future growth is dependent in part upon the development of new products, and there can be no assurance that such products will be developed.
7. We are subject to foreign currency exchange risk.
8. We need to attract and retain key employees to be competitive.

Read these in Item 1A · See the changes

1. Cybersecurity incidents and breaches or breakdowns of our information and technology systems or infrastructure could have a material adverse effect on our operations.Cybersecurity
2. The development, deployment and use of AI in our products and business operations generally could result in regulatory action, legal liability, operational challenges or reputational harm and our failure to adapt to medical technology industry trends and developments related to AI in a timely manner (or at all) could adversely affect our business, financial condition, results of operations and cash flows.newAI
3. A reduction or interruption in the supply of certain raw materials and components could adversely affect our operating results.
4. Interruption of our manufacturing or sterilization operations could adversely affect our business.
5. Cost volatility could adversely affect our operations.
6. Climate change and related sustainability efforts, or legal, regulatory or market measures to address these efforts, could adversely affect our business, financial condition or results of operations.reworded

Read these in Item 1A · See the changes

1. We are subject to lawsuits.
2. We are subject to extensive regulation.
3. Defects or quality issues associated with our products and related regulatory actions could adversely affect our results of operations and financial statements.reworded
4. Our operations are dependent in part on patents and other intellectual property assets.

Read these in Item 1A · See the changes

1. We may not be able to service all of our indebtedness.
2. The agreements that govern our indebtedness impose restrictions that may affect our ability to operate our businesses.

Read these in Item 1A · See the changes

1. The proposed combination of our Biosciences and Diagnostic Solutions business with Waters may not be completed, on the currently contemplated timeline or at all.new
2. The announcement and pendency of the combination of our Biosciences and Diagnostic Solutions business with Waters could cause disruptions in our business.new
3. We may not realize some or all of the expected benefits of the combination of our Biosciences and Diagnostic Solutions business with Waters.new
4. Risks Relating to the Spin-off of Embecta Corp.

Read these in Item 1A · See the changes

1. We cannot guarantee that any of our strategic acquisitions, investments or alliances will be successful.
2. Natural disasters, public health crises, war and other events beyond our control could disrupt our business and adversely affect our future revenues and operating income.reworded
3. Information About our Executive Officers

Read these in Item 1A · See the changes

Headings in the FY2024 10-K with no match this year.

1. We are subject to risks associated with public health crises, such as pandemics and epidemics, which could have a material adverse effect on our business. The nature and extent of impacts from any such events are highly uncertain and unpredictable.